Craig-Hallum analyst Alexander Nowak maintained a Buy rating on Stereotaxis (STXS – Research Report) today. The company’s shares closed last Friday at $1.48.
Nowak covers the Healthcare sector, focusing on stocks such as CareDx, REPRO-MED Systems, and Exact Sciences. According to TipRanks, Nowak has an average return of 0.0% and a 40.40% success rate on recommended stocks.
Stereotaxis has an analyst consensus of Strong Buy, with a price target consensus of $4.50.
See today’s best-performing stocks on TipRanks >>
Based on Stereotaxis’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $4.73 million and a GAAP net loss of $5.35 million. In comparison, last year the company earned a revenue of $7.04 million and had a GAAP net loss of $4.09 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stereotaxis, Inc. engages in the design, manufacture, and market of robotic systems and instruments that electrophysiologists use for the treatment of abnormal heart rhythms known as cardiac arrhythmias. Its products include The Epoch Solution, Niobe Magnetic Navigation System, Vdrive Robotic Navigation System, and Odyssey Solution. The company was founded in June 1990 and is headquartered in St. Louis, MO.
Read More on STXS:
- Stereotaxis management to meet virtually with Rosenblatt
- Stereotaxis says patient treated with Ensite X EP System with RMN System
- Stereotaxis and Abbott Combine Technologies in First Integrated Procedures to Treat Arrhythmia Patients
- Stereotaxis to Report Second Quarter 2023 Financial Results on August 10, 2023
- Stereotaxis to Initiate First-in-Human Trial to Support CE Mark Application of MAGiC Catheter
